Compare DAKT & GERN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | DAKT | GERN |
|---|---|---|
| Founded | 1968 | 1990 |
| Country | United States | United States |
| Employees | N/A | 258 |
| Industry | Office Equipment/Supplies/Services | Biotechnology: Pharmaceutical Preparations |
| Sector | Industrials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 944.7M | 808.3M |
| IPO Year | 1996 | N/A |
| Metric | DAKT | GERN |
|---|---|---|
| Price | $20.79 | $1.26 |
| Analyst Decision | | Hold |
| Analyst Count | 0 | 3 |
| Target Price | N/A | ★ $2.17 |
| AVG Volume (30 Days) | 231.4K | ★ 13.9M |
| Earning Date | 03-04-2026 | 05-06-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | ★ 0.75 | N/A |
| Revenue | ★ $608,932,000.00 | N/A |
| Revenue This Year | $12.06 | $26.91 |
| Revenue Next Year | $9.16 | $43.75 |
| P/E Ratio | $27.29 | ★ N/A |
| Revenue Growth | ★ 6.89 | N/A |
| 52 Week Low | $13.05 | $1.04 |
| 52 Week High | $28.27 | $2.01 |
| Indicator | DAKT | GERN |
|---|---|---|
| Relative Strength Index (RSI) | 59.01 | 34.40 |
| Support Level | $18.76 | $1.22 |
| Resistance Level | $21.14 | $1.29 |
| Average True Range (ATR) | 0.55 | 0.06 |
| MACD | 0.14 | -0.00 |
| Stochastic Oscillator | 89.72 | 21.15 |
Daktronics Inc designs and manufactures electronic scoreboards, programmable display systems, and large-screen video displays for sporting, commercial, and transportation applications. It is engaged in a full range of activities: marketing and sales, engineering and product design and development, manufacturing, technical contracting, professional services, and customer service and support. The company offers a complete line of products, from small scoreboards and electronic displays to large multimillion-dollar video display systems as well as related control, timing, and sound systems. The company has five reportable segments: Commercial, Live Events, High School Park and Recreation, Transportation, and International. The company makes the majority of its revenue from Live events.
Geron Corp is a biopharmaceutical company focused on blood cancers. Its telomerase inhibitor, RYTELO (imetelstat), is approved in the United States and European Union for certain adult patients with lower-risk myelodysplastic syndromes (LR-MDS) with transfusion-dependent anemia. RYTELO inhibits telomerase activity in malignant stem and progenitor cells, which may reduce abnormal cell proliferation while supporting the production of healthy cells. It is also conducting a Phase 3 trial of imetelstat in patients with JAK-inhibitor-refractory or relapsed myelofibrosis (R/R MF) and studies in other hematologic malignancies. The company operates as a single segment, being the development of therapeutic products for oncology.